Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2010

View Archived Issues

alpha2A-Adrenoceptor gene polymorphism and overexpression linked to type 2 diabetes

Prostanoid DP receptor antagonist AMG-853 safe in humans

Bepreve reduces allergen-induced ocular itching, nasal congestion and rhinorrhea in phase III trials

XF-73 and XF-70 active against pathogens relevant to biodefense

Submicron budesonide formulation may innovate pediatric asthma treatment

Vaccination with autologous HIV-1-pulsed DCs feasible in HIV

Janssen presents novel dopamine and serotonin receptor antagonists

Sanofi-aventis claims new cannabinoid CB1 receptor antagonists

Boehringer Ingelheim claims novel EGFR inhibitors

Nabi stockholders approve NicVAX option and license agreement

Capstone continues phase II trial of AZX-100 in keloid scarring

Bristol-Myers Squibb and Allergan enter global agreement on ExonHit's AGN-209323

Final dose level approved in Pluristem's phase I trial of PLX-PAD

Seattle Genetics achieves milestone under antibody-drug conjugate collaboration with Genentech

Enanta nominates EDP-239 as lead development candidate for HCV

FDA approves Novo Nordisk's Norditropin FlexPro prefilled growth hormone pen

NicOx grants Bausch & Lomb worldwide rights to NCX-116

Lilly and Transition Therapeutics enter into licensing and collaboration agreement

Solasia and Kyowa Hakko Kirin license agreement for SP-01 in Asia

Lundbeck and Takeda plan phase III trials of Lu-AA21004 and Lu-AA24530

Pfizer and Medivation report phase III results on Dimebon in Alzheimer's disease

Genzyme and PTC report on phase IIb ataluren trial in nmDBMD

Chiesi identifies novel muscarinic M3 receptor antagonists

Light Sciences Oncology completes enrollment in phase III Aptocine trial in MCRC

Advanced Cell Technology's RPE cells granted FDA orphan drug status / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...